

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

SUPPLEMENTAL ANNOUNCEMENT

References are made to the disclosure under the section headed “Compliance with the Model Code” in the annual results announcement of Clover Biopharmaceuticals, Ltd. (the “**Company**”) for the year ended December 31, 2025 dated March 25, 2026 (the “**Annual Results Announcement**”), and the disclosure under the section headed “MODEL CODE FOR SECURITIES TRANSACTIONS” in the 2025 annual report published by the Company on April 23, 2026 (the “**Annual Report**”). Unless otherwise defined herein, the terms used in this announcement shall have the same meanings as those defined in the Annual Results Announcement and Annual Report.

The Company hereby provides the supplemental information regarding the above-mentioned two sections as follows:

In order to avoid similar incidents in the future, the Company has reminded the Grantors of the importance of complying with the Model Code in their dealings in the Shares of the Company, and has also circulated share trading compliance guidelines to such persons to reiterate the relevant share trading compliance procedures.

In addition, the Company will strengthen the management of securities transactions by the Grantors, including by:

- notifying them of the specific blackout period schedule before the black-out period begins;
- requiring them to notify Dr. Liang and the Company before conducting any transaction in the Shares and to proceed only after Dr. Liang has expressly confirmed that the transaction may be carried out;
- reminding them to report to Dr. Liang and the Company within one day after the completion

of any transaction;

- conducting a quarterly refresh of the relevant requirements under the Model Code and the disclosure of interest regime to all Grantors, so as to proactively reinforce their awareness of the applicable obligations on an ongoing basis; and
- scheduling and holding a quarterly Teams meeting to reiterate all relevant compliance requirements, whereby Dr. Liang and the Grantors, together with the Company's Joint Company Secretary will conduct quarterly check-in communications to discuss any potential share dealing intentions and any other compliance matters.

Save as supplemented above, all other contents of the Annual Results Announcement and Annual Report remain unchanged.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, June 5, 2026

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG and Dr. Donna Marie AMBROSINO as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.